Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Humans – the weak link in drug development

This article was originally published in Scrip

Executive Summary

The announcement on 4 September that Gilead Sciences, after consultation with the FDA, will be dropping its experimental anti-hepatitis C virus (HCV) compound GS 9190 (tegobuvir) from ongoing clinical trials after two serious adverse events, will cast doubts on this potentially hot target in the treatment of HCV infections (scripintelligence.com, 5 September 2011).

You may also be interested in...



Stockwatch: Will Coronavirus Drug Developments Rescue The Sector’s Pricing Reputation?

Can the development of coronavirus vaccines and therapeutics reverse the demonization of the pharmaceutical sector brought about by drug price increases?

NASH Backlash: Intercept Delay Raises Questions

A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.

Stockwatch: Intercepting The Falling Knives Of NASH

A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.

Related Companies

UsernamePublicRestriction

Register

LL1133060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel